JCL Roundtable: Novel therapies in lipid management

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Managing lipid levels is a key focus of ASCVD prevention and treatment. This Journal of Clinical Lipidology Roundtable presents a conversation between Drs. Steven E. Nissen, Ann Marie Navar, Daniel Gaudet, and Kevin C. Maki who discussed novel lipid management options either recently approved or in development, including bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor, the cholesteryl ester transfer protein inhibitor obicetrapib, and apolipoprotein (Apo) C3 inhibiting agents. This conversation highlights the importance of primary prevention of ASCVD, ie, treating risk factors before they have progressed to cause major adverse cardiovascular events. The discussants describe the targets that are affected by these novel agents, including low-density lipoprotein cholesterol, lipoprotein(a), Apo B, Apo C3, triglycerides, remnant cholesterol, and chylomicron particles. Finally, the panelists expressed their excitement and optimism for these agents to become important elements of the toolbox for clinicians managing dyslipidemias.